The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1539
ISSUE 1539
January 29, 2018
Issue 1539
- A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
- Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
- L-Glutamine (Endari) for Sickle Cell Disease
- Neratinib (Nerlynx) for HER2-Positive Breast Cancer
- In Brief: Olmesartan and Sprue-Like Enteropathy
- In Brief: Severe Hypersensitivity Reactions with Rolapitant IV Emulsion (Varubi)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
January 29, 2018 (Issue: 1539)
The FDA has approved a two-dose hepatitis B virus
(HBV) vaccine (Heplisav-B – Dynavax) for use in adults
≥18 years old. The three other HBV vaccines marketed
in the US are usually administered in 3 doses. Engerix-B
and Recombivax HB are...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.